Plavix
Product Images NDC 54868-4070

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Plavix (NDC 54868-4070). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (75 mg label)

Plavix 75 mg tablet bottle label by Physicians Total Care, Inc. Contains 60 tablets of clopidogrel bisulfate. The label includes dosage information, lot number, expiration date, storage instructions, and barcode. A federal law caution prohibits dispensing without prescription.*

FDA Label Image

Chemical Structure (Plavix 01)

Chemical structure diagram showing the molecular formula of the active ingredient in Plavix, including a fused bicyclic ring containing sulfur and nitrogen, a chlorophenyl group, a methoxycarbonyl group, and a sulfate ion (H2SO4).*

FDA Label Image

Figure (Plavix 02)

A graph showing the effect of co-administered proton pump inhibitors (PPIs) Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg on the active metabolite AUC of Plavix. The plot includes mean values with 90% confidence intervals for change relative to Plavix administered alone, indicating a decrease in metabolite levels with these PPIs.*

FDA Label Image

Figure (Plavix 03)

A line graph depicting cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two lines compare Placebo (+ aspirin) showing higher event rates, and Plavix (+ aspirin) showing lower event rates. The graph includes a statistical significance marker (P=0.00009) and a note that other standard therapies were used as appropriate.*

FDA Label Image

Figure (Plavix 04)

A hazard ratio forest plot comparing event percentages for Plavix (+ aspirin) versus placebo (+ aspirin) across various baseline characteristics and concomitant medications or therapies. The chart shows subgroups by diagnosis, age, gender, race, enzyme elevation, ST depression, diabetes, previous myocardial infarction or stroke, and use of medications such as heparin, aspirin, GP IIb/IIIa antagonists, beta-blockers, ACE inhibitors, lipid-lowering agents, and PTCA/CABG. Each subgroup's point estimate and confidence interval are displayed, illustrating comparative event risk between the two treatments.*

FDA Label Image

Figure (Plavix 05)

A survival curve chart showing percentage of deaths before discharge over 28 days since randomization. It compares placebo to clopidogrel, noting a 7% proportional risk reduction with clopidogrel. The vertical axis shows percentage dead, and the horizontal axis shows days since randomization up to 28 days.*

FDA Label Image

Figure (Plavix 06)

A Kaplan-Meier curve comparing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. The chart contrasts outcomes for placebo versus clopidogrel groups, showing events percentages and noting a 9% proportional risk reduction with clopidogrel (p=0.002).*

FDA Label Image

Figure (Plavix 07)

This forest plot chart compares event percentages between Clopidogrel and placebo groups across various baseline categories such as sex, age, hours since onset, systolic blood pressure, heart rate, fibrinolytic agent given, prognostic index, and Metoprolol allocation. It displays odds ratios with confidence intervals and heterogeneity tests, highlighting a proportional reduction effect of Clopidogrel versus placebo.*

FDA Label Image

Figure (Plavix 08)

A forest plot chart comparing events and odds ratios between Clopidogrel and placebo groups across categories: Killip class, previous MI, and infarct location. The chart displays event percentages, odds ratio confidence intervals, and heterogeneity tests, summarizing a proportional reduction with Clopidogrel compared to placebo.*

FDA Label Image

Figure (Plavix 09)

A line graph showing the cumulative event rate percentage of fatal or non-fatal vascular events over months of follow-up for Plavix and Aspirin. The graph compares Plavix and Aspirin from 0 to 36 months, with Plavix showing a slightly lower event rate. A statistical significance marker with P=0.045 is included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.